ReviewJournal of nephrology2025
Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?
Review in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab has been advocated for as the first treatment choice for idiopathic membranous nephropathy. Currently, low-dose rituximab protocols are being implemented for the treatment of primary membranous nephropathy with CD19 B-cell monitoring in resource-limited settings. CD19 monitoring is a recently established monitoring tool for determining the optimal response to rituximab treatment, especially when using low-dose rituximab. This manuscript identifies the problems encountered with rituximab treatment, pitfalls in CD19 monitoring and its performance in relation to conventional monitoring tools like anti-PLA2R levels, level of proteinuria, and estimated glomerular filtration rate (eGFR). This article highlights the utility of low-dose, tailor-made regimens of rituximab in the Indian subcontinent with CD19 B cell monitoring to verify appropriate clinical response, along with the economic benefits of such modified regimens in resource-limited settings, based on current scientific evidence.
Indexed as
Identifiers
40193044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.